These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 34737044)

  • 21. Neurotoxic conversion of beta-synuclein: a novel approach to generate a transgenic mouse model of synucleinopathies?
    Fujita M; Sekigawa A; Sekiyama K; Sugama S; Hashimoto M
    J Neurol; 2009 Aug; 256 Suppl 3():286-92. PubMed ID: 19711118
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alpha-synuclein Immunization Strategies for Synucleinopathies in Clinical Studies: A Biological Perspective.
    Knecht L; Folke J; Dodel R; Ross JA; Albus A
    Neurotherapeutics; 2022 Sep; 19(5):1489-1502. PubMed ID: 36083395
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MerTK is a mediator of alpha-synuclein fibril uptake by human microglia.
    Dorion MF; Yaqubi M; Senkevich K; Kieran NW; MacDonald A; Chen CXQ; Luo W; Wallis A; Shlaifer I; Hall JA; Dudley RWR; Glass IA; ; Stratton JA; Fon EA; Bartels T; Antel JP; Gan-Or Z; Durcan TM; Healy LM
    Brain; 2024 Feb; 147(2):427-443. PubMed ID: 37671615
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
    Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
    J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation.
    Fagerqvist T; Lindström V; Nordström E; Lord A; Tucker SM; Su X; Sahlin C; Kasrayan A; Andersson J; Welander H; Näsström T; Holmquist M; Schell H; Kahle PJ; Kalimo H; Möller C; Gellerfors P; Lannfelt L; Bergström J; Ingelsson M
    J Neurochem; 2013 Jul; 126(1):131-44. PubMed ID: 23363402
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Is Cell Death Primary or Secondary in the Pathophysiology of Idiopathic Parkinson's Disease?
    Schulz-Schaeffer WJ
    Biomolecules; 2015 Jul; 5(3):1467-79. PubMed ID: 26193328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic approaches to target alpha-synuclein pathology.
    Brundin P; Dave KD; Kordower JH
    Exp Neurol; 2017 Dec; 298(Pt B):225-235. PubMed ID: 28987463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathological and clinical aspects of alpha/beta synuclein in Parkinson's disease and related disorders.
    Tolmasov M; Djaldetti R; Lev N; Gilgun-Sherki Y
    Expert Rev Neurother; 2016 May; 16(5):505-13. PubMed ID: 26959397
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AAV-mediated expression of a new conformational anti-aggregated α-synuclein antibody prolongs survival in a genetic model of α-synucleinopathies.
    Düchs M; Blazevic D; Rechtsteiner P; Kenny C; Lamla T; Low S; Savistchenko J; Neumann M; Melki R; Schönberger T; Stierstorfer B; Wyatt D; Igney F; Ciossek T
    NPJ Parkinsons Dis; 2023 Jun; 9(1):91. PubMed ID: 37322068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting intracellular and extracellular alpha-synuclein as a therapeutic strategy in Parkinson's disease and other synucleinopathies.
    Vekrellis K; Stefanis L
    Expert Opin Ther Targets; 2012 Apr; 16(4):421-32. PubMed ID: 22480256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ELISA method to detect α-synuclein oligomers in cell and animal models.
    Lassen LB; Gregersen E; Isager AK; Betzer C; Kofoed RH; Jensen PH
    PLoS One; 2018; 13(4):e0196056. PubMed ID: 29698510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Generation of monoclonal antibodies against phosphorylated α-Synuclein at serine 129: Research tools for synucleinopathies.
    Fayyad M; Majbour NK; Vaikath NN; Erskine D; El-Tarawneh H; Sudhakaran IP; Abdesselem H; El-Agnaf OMA
    Neurosci Lett; 2020 Apr; 725():134899. PubMed ID: 32156613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treating Parkinson's Disease with Antibodies: Previous Studies and Future Directions.
    Castonguay AM; Gravel C; Lévesque M
    J Parkinsons Dis; 2021; 11(1):71-92. PubMed ID: 33104039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SMG1 identified as a regulator of Parkinson's disease-associated alpha-synuclein through siRNA screening.
    Henderson-Smith A; Chow D; Meechoovet B; Aziz M; Jacobson SA; Shill HA; Sabbagh MN; Caviness JN; Adler CH; Driver-Dunckley ED; Beach TG; Yin H; Dunckley T
    PLoS One; 2013; 8(10):e77711. PubMed ID: 24204929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy.
    Gerson JE; Farmer KM; Henson N; Castillo-Carranza DL; Carretero Murillo M; Sengupta U; Barrett A; Kayed R
    Mol Neurodegener; 2018 Mar; 13(1):13. PubMed ID: 29544548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conformation-specific Antibodies Targeting Aggregated Forms of α-synuclein Block the Propagation of Synucleinopathy.
    Choi M; Kim TK; Ahn J; Lee JS; Jung BC; An S; Kim D; Lee MJ; Mook-Jung I; Lee SH; Lee SJ
    Exp Neurobiol; 2022 Feb; 31(1):29-41. PubMed ID: 35256542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.
    Rabl R; Breitschaedel C; Flunkert S; Duller S; Amschl D; Neddens J; Niederkofler V; Rockenstein E; Masliah E; Roemer H; Hutter-Paier B
    BMC Neurosci; 2017 Jan; 18(1):22. PubMed ID: 28143405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. α-Synuclein pathology in Parkinson's disease and related α-synucleinopathies.
    Henderson MX; Trojanowski JQ; Lee VM
    Neurosci Lett; 2019 Sep; 709():134316. PubMed ID: 31170426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.
    Sengupta U; Guerrero-Muñoz MJ; Castillo-Carranza DL; Lasagna-Reeves CA; Gerson JE; Paulucci-Holthauzen AA; Krishnamurthy S; Farhed M; Jackson GR; Kayed R
    Biol Psychiatry; 2015 Nov; 78(10):672-83. PubMed ID: 25676491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.